16-1229569-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_024164.6(TPSB2):c.230G>A(p.Gly77Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000144 in 1,525,592 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000015 ( 0 hom., cov: 18)
Exomes 𝑓: 0.000014 ( 0 hom. )
Consequence
TPSB2
NM_024164.6 missense
NM_024164.6 missense
Scores
3
10
Clinical Significance
Conservation
PhyloP100: 0.133
Genes affected
TPSB2 (HGNC:14120): (tryptase beta 2) Tryptases comprise a family of trypsin-like serine proteases, the peptidase family S1. Tryptases are enzymatically active only as heparin-stabilized tetramers, and they are resistant to all known endogenous proteinase inhibitors. Several tryptase genes are clustered on chromosome 16p13.3. These genes are characterized by several distinct features. They have a highly conserved 3' UTR and contain tandem repeat sequences at the 5' flank and 3' UTR which are thought to play a role in regulation of the mRNA stability. These genes have an intron immediately upstream of the initiator Met codon, which separates the site of transcription initiation from protein coding sequence. This feature is characteristic of tryptases but is unusual in other genes. The alleles of this gene exhibit an unusual amount of sequence variation, such that the alleles were once thought to represent two separate genes, beta II and beta III. Beta tryptases appear to be the main isoenzymes expressed in mast cells, whereas in basophils, alpha-tryptases predominate. Tryptases have been implicated as mediators in the pathogenesis of asthma and other allergic and inflammatory disorders. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.17342821).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TPSB2 | NM_024164.6 | c.230G>A | p.Gly77Glu | missense_variant | 3/6 | ENST00000606293.5 | NP_077078.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TPSB2 | ENST00000606293.5 | c.230G>A | p.Gly77Glu | missense_variant | 3/6 | 1 | NM_024164.6 | ENSP00000482743.1 | ||
TPSB2 | ENST00000612142.1 | c.251G>A | p.Gly84Glu | missense_variant | 2/5 | 1 | ENSP00000478695.1 | |||
TPSB2 | ENST00000611196.4 | n.230G>A | non_coding_transcript_exon_variant | 3/8 | 1 | ENSP00000484461.1 |
Frequencies
GnomAD3 genomes AF: 0.0000155 AC: 2AN: 129294Hom.: 0 Cov.: 18
GnomAD3 genomes
AF:
AC:
2
AN:
129294
Hom.:
Cov.:
18
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000561 AC: 1AN: 178232Hom.: 0 AF XY: 0.0000103 AC XY: 1AN XY: 96642
GnomAD3 exomes
AF:
AC:
1
AN:
178232
Hom.:
AF XY:
AC XY:
1
AN XY:
96642
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000143 AC: 20AN: 1396210Hom.: 0 Cov.: 33 AF XY: 0.0000174 AC XY: 12AN XY: 690522
GnomAD4 exome
AF:
AC:
20
AN:
1396210
Hom.:
Cov.:
33
AF XY:
AC XY:
12
AN XY:
690522
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000155 AC: 2AN: 129382Hom.: 0 Cov.: 18 AF XY: 0.0000321 AC XY: 2AN XY: 62386
GnomAD4 genome
AF:
AC:
2
AN:
129382
Hom.:
Cov.:
18
AF XY:
AC XY:
2
AN XY:
62386
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 25, 2024 | The c.230G>A (p.G77E) alteration is located in exon 3 (coding exon 2) of the TPSB2 gene. This alteration results from a G to A substitution at nucleotide position 230, causing the glycine (G) at amino acid position 77 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
PrimateAI
Uncertain
T
Sift4G
Benign
T;T
Vest4
MutPred
Gain of disorder (P = 0.2511);.;
MVP
ClinPred
T
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at